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We have screened a subtracted cDNA library in
order to identify differentially expressed genes in
omental adipose tissue of human patients with
Type 2 diabetes. One clone (#1738) showed a marked
reduction in omental adipose tissue from patients
with Type 2 diabetes. Sequencing and BLAST ana-
lysis revealed clone #1738 was the adipocyte-speci-
fic secreted protein gene apM1 (synonyms ACRP30,
AdipoQ, GBP28). Consistent with the murine ortho-
logue, apM1 mRNA was expressed in cultured
human adipocytes and not in preadipocytes.
Using RT-PCR we confirmed that apM1 mRNA
levels were significantly reduced in omental adipose
tissue of obese patients with Type 2 diabetes com-
pared with lean and obese normoglycemic subjects.
Although less pronounced, apM1 mRNA levels
were reduced in subcutaneous adipose tissue of
Type 2 diabetic patients. Whereas the biological
function of apM1 is presently unknown, the tissue
specific expression, structural similarities to TNFx,
and the dysregulated expression observed in obese
Type 2 diabetic patients suggest that this factor
may play a role in the pathogenesis of insulin re-
sistance and Type 2 diabetes.
Keywords: Adiponectin, Acrp30, GBP28, AdipoQ, subtractive
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INTRODUCTION
Obesity is a major health problem in industria-
lized countries, and is accompanied by a host of
clinical conditions including insulin resistance,
Type 2 diabetes, hypertension, and vascular
disease (collectively referred to as Syndrome X).
However, the molecular and pathophysiological
mechanisms of obesity, insulin resistance, and
Type 2 diabetes are poorly understood. Several
tissues appear to be central to the pathogenesis
of obesity and Type 2 diabetes including the
brain, adipose tissue, skeletal muscle, and liver.
Adipose tissue is highly specialized, and
plays important roles in glucose homeostasis,
lipid synthesis and metabolism, and energy
storage.
1, 2j More recently, the role of adipose tis-
sue as a passive storage depot has changed to
that of a true endocrine organ. Several proteins
important in the regulation of glucose and fatty
acid metabolism are secreted by adipocytes.
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For example, tumor necrosis factor c (TNFc) is
secreted by adipocytes and is elevated in adi-
pose tissue and circulating plasma of humans
with obesity. TM Interestingly, TNFc interferes
with insulin receptor signaling and inhibits
insulin-stimulated glucose transport I41 provid-
ing a possible mechanism of obesity related in-
sulin resistance. Leptin is another cytokine
secreted from adipocytes that in animal models
has been shown to regulate appetite, energy ex-
penditure, and adiposity. I5 Lastly, plasminogen
activator inhibitor-1 (PAI-1) is secreted from adi-
pose tissue. Both mRNA and plasma levels of
PAI-1 were found to be positively correlated
with the amount of omental/intra-abdominal
adiposity. I6"71 Thus, through the secretion of
these, and possibly other, cytokines adipose tis-
sue actively participates in the pathogenesis of
Syndrome X.
Recently, another novel adipose-specific gene
was isolated based on differential expression
from 3T3-L1 adipoctyes,
Is, 91 and was later found
in human adipose tissue. I101 ApM1 (synonyms:
Acrp30, AdipoQ, GBP28), encodes a 28-30 kDa
secreted protein that is structurally similar to
complement factor Clq L81, and TNFc. [11] In the
present study, we analyzed a subtracted cDNA
library from omental adipose tissue of human
patients with Type 2 diabetes to identify dif-
ferentially expressed genes in human adipose
associated with diabetes. Herein we report that
apM1 mRNA is reduced in omental and to a
lesser degree in subcutaneous adipose tissue of
human Type 2 diabetic patients. These findings
provide additional data characterizing apM1 ex-
pression and suggest a potential role for apM1
in insulin resistance and Type 2 diabetes.
MATERIALS AND METHODS
Materials
Abdominal omental and subcutaneous adipose
tissue was collected at Eastern Carolina
University Medical Center from patients under-
going gastric bypass surgery (obese non-diabetic
and obese Type 2 diabetic subjects) or elective
abdominal surgery (lean non-diabetic subjects).
Informed consent was obtained from all pa-
tients used in the study prior to tissue collection,
and the protocols approved by the Institutional
Review Board at Eastern Carolina University.
Donors were categorized as lean non-diabetic,
obese non-diabetic or obese Type 2 diabetic
based on presurgical examinations and records
(Tab. I). Human preadipocytes and differen-
tiated adipocytes (ZenBio, Research Triangle
Park, NC) were isolated from subcutaneous
adipose tissue from I male and 2 female patients
(age 33- 55,BMI 20.9 25.1). The cells were
cultured under 95%/5% O2/CO2, at 37C in
DMEM/Ham’s F10 (1:1) containing 3% fetal
calf serum, 60U/ml penicillin/streptomycin,
25 tg/ml fungizone with or without 100nM
insulin and 1 tM dexamethasone (for adipocytes
and preadipocytes, respectively).
Generation and Screening of Subtracted
cDNA Libraries
Total RNA was isolated from omental adipose
tissue from 4 obese non-diabetic and 4 obese
Type 2 diabetic female patients (Tab. I) using 4M
guanidine isothiocyanate solution (Gibco, BRL)
and phenol choloroform extraction, cDNA was
synthesized from total RNA using SMARTTM
cDNA synthesis kit (Clontech, Palo Alto, CA),
and a subtracted cDNA library was generated
for obese non-diabetic minus obese diabetic
omental adipose tissue by Suppression PCRTM
(Clontech). Approximately 9200 independent
clones were randomly picked into 96-well plates
(alternately, plasmid cDNA of the clones was
alkaline denatured) and arrayed in duplicate
onto charged nylon membranes (Amersham,
Piscataway, NJ) using a PBA Flexys robot
(Genomic Solutions, Ann Arbor, MI). Clones
were identified by differential hybridization to
gap-labeled cDNA probes generated by reverseREDUCED apM1 mRNA IN TYPE 2 DIABETES 83
TABLE Clinical characteristics of human adipose tissue donors used in the analysis of apM1 expression
Age BMI Fasting Plasma Glucose Fasting Plasma Insulin
(years) (kg/m2) (mg/dl) (tU/ml)
Subtracted Library
Obese non-diabetic 4 50.5 4- 3.3 52.9 4- 4.2 103 4-1.9 17.5 4- 5.8
Type 2 diabetic 4 48.5 4- 4.2 51.3 4- 6.1 175 4- 22.5* 32.3 4- 7.2
Omental Adipose Tissue
Lean 6 37.7 4- 4.1 22.2 4-1.3 ND ND
Obese non-diabetic 10 37.5 4- 4.8 51.5 4- 4.0
b 97.3 + 3.2 21.7 4- 4.0
Type 2 diabetic 8 45.1 + 2.7 53.7 4- 3.1
b 185.7 4-19.4"* 29.2 4- 6.1
Subcutaneous Adipose Tissue
Lean 7 55.1 + 7.5 22.5 4- 0.9 ND ND
Obese non-diabetic 9 40.2 4- 5.6 51.1 4- 3.9
b 89.9 4- 5.1 17.4 4- 3.8
Type 2 diabetic 8 46.7 4- 2.2 47.3 4- 3.5
b 183.6 4- 21.3"* 33.2 + 8.7
Data are shown as means 4-SEM.
bp 0.001 one-way ANOVA with Tukey post hoc test.
P K 0.01 Student’s t-test.
P _
0.0001 Student’s t-test.
ND not determined.
transcription of 10ug total RNA (isolated
from the same patients used to construct the
library) using an Oligo dT primer and Super-
script IITM reverse transcriptase (Gibco BRL).
Putative differentially expressed clones were se-
quenced, and subjected to BLAST analysis.
Semi-quantitative Reverse Transcription
Polymerase Chain Reaction (RT-PCR)
First strand cDNA was prepared in duplicate
from 0.1, 0.5 and 1.0ug of DNaseI treated total
RNA using Oligo dT and Superscript IITM
reverse transcriptase (Gibco BRL). Primer con-
centration, annealing temperature, template con-
centration, and cycle number were optimized
for apM1 and rS9 amplifications. Duplicate
PCR reactions (50tl) were incubated at 94C
2min (to denature TaqStart antibody), and
then cycled at 94C 30s, 60C 30s, 72C lmin.
Aliquots were taken from each reaction during
exponential amplification at 23, 27 and 30 cycles.
Quantification of PCR products was based on
Southern blots of the reactions using internal
32P-labeled oligonucleotide probes to apM1
and rS9. Replication of experimental results in
omental and subcutaneous adipose tissue was
performed for each patient using identical
conditions on independently prepared sam-
ples of cDNA as above. To test whether genes
identified by differential hybridization were
expressed in adipocytes (as opposed to macro-
phages or vascular endothelial cells associated
with adipose tissue), Iug of DNaseI treated
total RNA pooled from 3 patients was reverse
transcribed to cDNA. ApM1 and rS9 were
amplified by PCR for 30 cycles using identical
conditions as above.
Image and Statistical Analysis
Image analysis for all hybridization studies was
performed using a PersonalFX phosphorimager
and QuantityOne software (BioRad, Hercules,
CA) or AIS (Imaging Research Inc., Ontario,
Canada) imaging software for colony arrays. Nor-
malized apM1 levels were compared by one-
way ANOVA with post hoc tests (for multiple
group comparisons) or Student’s t-test (for com-
parisons between two groups).
RESULTS
In order to identify novel genes that are dif-
ferentially expressed in adipose tissue of human84 M.A. STATNICK et al.
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FIGURE 1 High-density analysis of differential gene expression in omental adipose tissue from obese non-diabetic and obese
Type 2 diabetic patients. Analysis of differential gene expression on cDNA arrays identified apM1 as a potential regulated gene.
Both blots were hybridized to Oligo dT-primed 32p-labeled first strand cDNA synthesized from 10 tg total RNA isolated from
obese non-diabetic or obese Type 2 diabetic patients, respectively, normalized to cpm probe/ml hybridization buffer.
M 1 2 3 4 M
apM1
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FIGURE 2 Expression of apM1 mRNA by RT-PCR in human preadipocytes and mature adipocytes. Amplification of apM1 or
ribosomal $9 (control) was performed using Oligo dT-primed cDNA synthesized from tg DNaseI treated total RNA following
30 cycles of PCR. Reverse transcriptase negative samples were used to assess contamination by genomic DNA. (M) 100bp DNA
ladder, (1) preadipocyte cDNA, (2) preadipocyte RT-control, (3) adipocyte cDNA, (4) adipocyte RT-control.
patients with Type 2 diabetes, we randomly
screened a subtracted cDNA library enriched in
mRNAs overexpressed in obese non-diabetic
patients. Using differential hybridization of col-
ony/cDNA arrays, one clone (#1738) consistently
showed a marked reduction (approximately 4-6REDUCED apM1 mRNA IN TYPE 2 DIABETES 85
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FIGURE 3 Semiquantitative RT-PCR analysis of apM1 expression in human adipose tissue. Expression of apM1 mRNA in
omental adipose tissue isolated from the patients used in the generation and screening of the subtracted cDNA library (A).
Expression of apM1 mRNA in omental adipose tissue isolated from lean, obese non-diabetic and obese Type 2 diabetic
individuals (B). Expression of apM1 mRNA in subcutaneous adipose tissue isolated from lean, obese non-diabetic and obese
Type 2 diabetic individuals (C). Analysis of amplified apM1 and $9 products was performed after 23 cycles and 27 cycles in
omental and subcutaneous adipose tissue, respectively. These cycles were found to be within the exponential phase of the
respective PCR reactions. *= P < 0.05 compared to obese non-diabetic individuals by Student’s t-test, b P < 0.01 compared to a
groups by one-way ANOVA. c not significant, P < 0.1 compared to lean individuals by one-way ANOVA. Data shown are
shown as means + S.E.M. for each group.
fold) from patients with Type 2 diabetes (Fig. 1).
Sequencing #1738 and subsequent BLAST ana-
lysis revealed that this clone was identical to a
recently cloned adipose-specific gene apM1.
[10]
Consistent with earlier reports on the murine
orthologue Acrp30/AdipoQ,
[8, 9] apM1 mRNA
was readily detectable in mature human adipo-
cytes but not in preadipocytes (Fig. 2). These
data verify that apM1 is expressed in human
adipocytes.86 M.A. STATNICK et al.
To confirm our findings from colony arrays,
expression of apM1 was analyzed by semiquan-
titative RT-PCR. Consistent with our previous
data, expression of apM1 was reduced 4.8 fold
in the omental adipose tissue of Type 2 diabetic
patients (normalized apM1=0.39+0.17)com-
pared to the non-diabetic obese subjects (nor-
malized apM1 1.91 4-0.19) used to generate the
subtracted library (Fig. 3A). We next compared
apM1 expression in omental adipose tissue from
lean, obese non-diabetic, and obese Type 2 dia-
betic patients. Interestingly, expression of apM1
was reduced approximately 2.2-2.5 fold in
omental adipose tissue from Type 2 diabetic
patients (normalized apM1 0.70 4- 0.15, n 8)
compared to lean (normalized apM1=1.774-
0.21, n=6) or obese non-diabetic (normalized
apM1 1.55 4- 0.33, n 10) individuals (Fig. 3B).
In order to determine whether abnormalities in
apM1 expression exist in other adipose depots,
we analyzed apM1 in subcutaneous adipose
tissue. As can be seen in Figure 3C, apM1
was reduced 2 fold in subcutaneous adipose
tissue from diabetic patients (normalized
apM1 0.07 4- 0.03, n 8) compared to lean pa-
tients (normalized apM1=0.144-0.03, n=7),
while obese non-diabetic individuals exhib-
ited intermediate apM1 levels (normalized
apM1 0.10 4- 0.02, n 9). Thus, it appears that
apM1 levels are reduced in both adipose depots
in obese patients with Type 2 diabetes.
DISCUSSION
In the present study we sought to identify genes
that are differentially expressed in omental
adipose tissue of patients with Type 2 diabetes.
Interestingly, we identified apM1 from a small
group of patients whose expression is reduced
with diabetes. ApM1 (synonyms: Acrp30, Adi-
poQ, GBP28) encodes a 244 amino acid protein
(known as adiponectin) that is most homologous
to complement factor Clq. Moreover, the crystal
structure Elll and gene organization
[13] of apM1
indicate that this gene has many similarities to
TNFc. Previous studies have shown that the
murine orthologue of apM1, Acrp30/AdipoQ,
is expressed exclusively in adipose tissue. Con-
sistent with these data, we found that apM1
mRNA is expressed only in the fully differen-
tiated human adipocytes and not in preadipo-
cytes. Therefore, it appears that apM1 encodes
another cytokine secreted from adipocytes.
Unlike the other adipose-secreted cytokines
(leptin, TNFc, and PAI-1), Hu et al. (1996)
reported that apM1/Acrp30/AdipoQ mRNA
levels were reduced in subcutaneous adipose
tissue of obese humans and in ob/ob mice.
Recently, a Japanese study reported that plas-
ma levels of apM1 were negatively correlated
with BMI. I121 Interestingly, the correlation be-
tween BMI and apM1 was stronger in male
(r=- 0.71) compared to female (r=- 0.51) sub-
jects. Moreover, apM1 levels were significantly
higher in women compared to men, independ-
ent of adiposity. In this regard circulating
apM1 is similar to leptin, which is also elevat-
ed in women compared to men per unit of fat
mass.
[14] These data suggest that gender-based
differences exist in the regulation of apM1 gene
expression.
In the patients used in the present study, we
were unable to detect a significant change in
apM1 expression in either omental or subcuta-
neous adipose tissue associated with obesity in
the absence of frank diabetes. These findings
contrast with an earlier study 91 that reported
a reduction in apM1 mRNA in obese humans.
Since the previous study employed a more
accurate Northern blot analysis, one might
speculate that the disparity in results was
generated by our use of RT-PCR. However, we
found that leptin mRNA levels were elevated
4-6 fold with obesity in our patients using
RT-PCR under identical conditions (data not
shown), validating our technique with data from
previous studies. [15’161 A more likely source
for the disparity in findings is the small num-
ber of patients used in this and previous9REDUCED apM1 mRNA IN TYPE 2 DIABETES 87
studies. Moreover, our patients were women,
which exhibit greater variability in apM1
levels in comparison with men.
[12] Therefore,
future studies should focus on expanding the
numbers of patients analyzed, paying appro-
priate attention to the gender of the patients.
While apM1 secretion rate is increased by
insulin
Isj and apM1 mRNA is reduced in the
insulin resistant ob/ob mouse,
Igj we found no
correlation in apM1 mRNA with fasting insulin
(r2=0.15). However, we found the most pro-
nounced reduction in apM1 was in omental
adipose tissue, the fat depot most strongly cor-
related with development of insulin resistance
and Type 2 diabetes. [17-191 In addition, the
chromosomal location of the apM1 gene is in a
susceptibility locus for Familial Combined Hy-
perlipidaemia and polygenic Type 2 diabetes. [13]
Based on these data, an intriguing consideration
is that reduced apM1 levels somehow partici-
pate in the development of Type 2 diabetes. As
the function and signaling properties of apM1
are presently unknown, future studies will be
necessary to determine its role in the pathophy-
siology of obesity and Type 2 diabetes.
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